West Pharmaceutical Services (WST) Receivables (2009 - 2026)

West Pharmaceutical Services (WST) has reported Receivables for 18 consecutive years, with $712.0 million the latest figure, recorded in Q2 2026.

• Quarterly Receivables rose 22.25% year-over-year to $712.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $712.0 million (up 22.25% YoY) and the FY2025 annual result came in at $586.3 million, up 1.82% from the prior year.
• Receivables climbed to $712.0 million in Q2 2026 per WST's latest filing, from $685.6 million in the prior quarter.
• Over the last five years, Receivables for WST reached as high as $712.0 million in Q2 2026 and fell as low as $23.8 million in Q4 2025.
• A 5-year average of $522.0 million and a median of $526.4 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2025 — Receivables sank 95.87% — and 2026, when it gained 26.12%.
• Year by year, Receivables stood at $507.4 million in 2022, then gained by 5.14% to $533.5 million in 2023, then grew by 7.93% to $575.8 million in 2024, then plunged by 95.87% to $23.8 million in 2025, then jumped by 2891.6% to $712.0 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $712.0 million, $685.6 million, and $23.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.